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Abstract 
Background and aims 
Epidemiological evidence suggests an association between consumption of tomato products 
or lycopene and lower risk for cardiovascular diseases (CVD). Our aim was to evaluate the 
state of the evidence from intervention trials on the effect of consuming tomato products and 
lycopene on markers of cardiovascular (CV) function. We undertook a systematic review and 
meta-analysis on the effect of supplementing tomato and lycopene on CV risk factors. 
Methods  
Three databases including Medline, Web of science, and Scopus were searched from inception 
to August 2016. Inclusion criteria were: intervention randomised controlled trials reporting 
effects of tomato products and lycopene supplementation on CV risk factors among adult 
subjects >18 years of age. The outcomes of interest included blood lipids (total-, HDL-, LDL-
cholesterol, triglycerides, Oxidised-LDL), endothelial function (flow-mediated dilation 
(FMD), pulse wave velocity (PWV)) and blood pressure (BP). Random-effects models were 
used to determine the pooled effect sizes. 
Results 
Out of 1189 publications identified, 17 fulfilled inclusion criteria and were meta-analysed. 
Overall, interventions supplementing tomato were associated with significant reductions in 
LDL-cholesterol (-0.22 mmol/L; p=0.006) and improvements in FMD (2.53%; p=0.01); 
while lycopene supplementation reduced Systolic-BP (-5.66 mmHg; p=0.002). No other 
outcome was significantly affected by these interventions.  
Conclusions 
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The available evidence on the effects of tomato products and lycopene supplementation on 
CV risk factors supports the view that increasing the intake of these has positive effects on 
blood lipids, blood pressure and endothelial function. These results support the development 
of promising individualised nutritional strategies involving tomatoes to tackle CVD.  
Keywords 
Tomato, Lycopene, Intervention, cardiovascular risk factors, endothelial function, blood 
pressure, blood lipids, systematic review, meta-analysis 
  
 4 
Introduction 
Globally, behavioural risk factors including a range of dietary risks, e.g. low intakes of fruit 
and vegetables, have the greatest potential to promote disease and impair human health [1]. A 
wealth of epidemiological evidence indicates that particularly cardiovascular health is 
strongly influenced by a healthy diet; fruit and vegetables are considered an important 
element of a cardio-protective diet [2].  
The benefit of consuming fruit and vegetables is often ascribed to specific components of 
food. Recent systematic reviews of the literature indicate that supplementation with dietary 
nitrates, or foods rich in these compounds such as beetroot, have the potential to lower blood 
pressure [3] and improve endothelial function [4], both regarded as early indicators of 
cardiovascular diseases (CVD). These benefits are valuable when developing effective 
nutritional strategies targeting specific key metabolic risk factors for the prevention and 
management of CVD.  
Vegetables such as tomato are ubiquitous in most dietary patterns across the world and their 
contribution to health has been documented in longitudinal epidemiologic studies. High self-
reported intakes of tomato and tomato products, and of dietary lycopene (a carotenoid 
compound) are associated with lower risk for CVD [5, 6]. Lycopene is one of the most potent 
antioxidants and the most predominant carotenoid in human plasma and it is assumed to be 
one of the active compounds on the health benefits of tomato [7].  While the epidemiological 
evidence indicates a consistent association between tomato products and/or lycopene and 
lower CVD risk [5, 6], the effect of nutritional interventions on tomato products and lycopene 
have been studied only recently and their efficacy on improving vascular function remains to 
be evaluated. The evidence from human intervention trials on the efficacy of tomato products 
or lycopene supplementation on oxidative stress and marker of subclinical inflammation (hs-
CRP, IL-6) have been previously reviewed and meta-analysed [8]. However, others 
cardiovascular risk biomarkers, such as blood lipids (total-, HDL-, LDL-cholesterol, 
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triglycerides, Oxidised-LDL) and endothelial function (FMD, PWV) have not been reviewed 
previously and a critical appraisal of the literature should be useful in testing this hypothesis. 
Here, we report the findings of a systematic review and meta-analysis of the evidence from 
intervention trials investigating the efficacy of tomato products or lycopene supplementation 
on cardiovascular (CV) risk factors in adult human individuals.  
Methods 
This systematic review was conducted according to Cochrane [9] and the Centre for Reviews 
and Dissemination guidelines [10] and is reported according to PRISMA guidelines [11] 
(Figure 1 and Table S1). The protocol has been registered with PROSPERO, the International 
Prospective Register of Systematic Reviews (Registration number CRD42016042092).  
In August 2016, three electronic databases were searched systematically from inception: 
Medline, Web of science, and Scopus. Reference lists of identified publications were hand 
searched to identify other studies potentially eligible for inclusion. 
The search strategy included the following terms 1) tomato; 2) lycopene; 3) trial/clinical 
trials; 4) vascular risk factors; 5) biomarkers; 6) vascular function; 7) endothelial function; 8) 
blood lipids. The systematic review was restricted to articles published in English. 
Two researchers (HMC, JL) assessed articles independently for eligibility. The decision to 
include studies was hierarchical and made initially on the basis of the studies titles and 
abstracts. When a study could not be excluded with certainty based on the screening of titles 
and abstract, the full-text of the article was evaluated to decide its inclusion or exclusion. 
When full agreement had been reached, the article was either discarded or moved to the next 
phase (full text screening). The full text of the selected articles was independently assessed 
by the same researchers. 
Inclusion/exclusion criteria  
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The selection of suitable references during the search strategy and the data extraction was 
performed according to specific criteria which are delineated below: 
Inclusion criteria included: 1) Study Design: intervention studies; 2) Subjects: adult 
subjects >18 years of age; 3) Interventions: nutritional/dietary interventions (tomato and 
tomato-based products or lycopene supplements versus a control or placebo group); 4) 
Outcomes: CV health-related outcome measures (described below). Exclusion criteria 
included 1) Study Design: non-interventional studies; 2) Subjects: subjects <18 years of age; 
3) Interventions: interventions not involving tomato or lycopene, or interventions combined 
interventions in which the effects of tomato and lycopene cannot be singled out; 4) 
Outcomes: non-vascular outcome measures.  
Data extraction 
 
A standardized, pre-piloted form was used to extract data from the included studies for 
assessment of study quality and evidence synthesis. Extracted information included: study 
design (country, methods of recruitment, follow-up length, methods of analysis, completion 
rates; participant characteristics (population and setting, inclusion/exclusion criteria, baseline 
characteristics); description of measurement methods; outcome measures (dietary/nutritional 
intake, body weigh/composition, CV biomarkers); intervention details (i.e. tomato or 
lycopene), and information to assess the risk of bias. Study quality was assessed using the 
Cochrane risk of bias tool [18]. 
Outcome measures 
 
The primary outcomes of the analyses were changes in CV risk factors after tomato or 
lycopene supplementation. Measures included blood lipids (Total-, LDL-, and HDL-
cholesterol, Triglycerides, Oxidized-LDL), assessment of endothelial function by flow-
mediated dilation (FMD), pulse wave velocity (PWV) and resting blood pressure, systolic 
(SBP) and diastolic (DBP).  
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Statistical analysis 
 
Review Manager (RevMan Version 5.1 for Windows Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2011) was used to pool and meta-analyse results from 
the individual studies. Pooled results are reported as weighted mean differences with 95% CI 
and with two-sided P-values. A random effects model accounting for inter-study variation 
was used, thereby minimizing potential bias due to methodological differences between 
studies. Multiple dietary intervention arms from three studies were included in the meta-
analysis. As suggested by Higgins et al. [9], excessive weightings from “double counts” 
originating from the “shared” group (that is, the control group) were controlled by splitting 
the sample size of the shared group into approximately equal smaller groups for the 
comparisons; the means and standard deviations were left unchanged. When available, we 
used results from multivariate models with the most complete adjustment for potential 
confounders reported in original studies.  
Statistical heterogeneity was evaluated using the I2 statistic [9, 10]; the 95% CI for I2 were 
calculated using Higgins et al.’s method [12, 13]. Where I2 was >50%, the degree of 
heterogeneity was considered high. Publication bias was appraised by visual inspection of a 
funnel plot of effect size against the standard error (SE), with asymmetry assessed formally 
with Egger’s regression test [14]. Quality of studies was assessed using the Jadad system 
[15]. 
Results  
 
The searches yielded 1189 publications after de-duplication and results of the screening 
process are described in Figure 1. Seventeen publications that met our inclusion criteria were 
included in the present systematic review and meta-analysis (Table 1) [16-32]. 
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Study characteristics 
Twelve studies used a RCT design while five were controlled trials using a non-randomised 
design. These 17 studies originated from the USA (n=3), UK (n=2), Greece (n=3), Israel 
(n=3), and single studies from Finland, Germany, Korea, Mexico, India, and Australia. 
The pooled study population meta-analysed included 932 participants who were followed-up 
for 2 months on average (range from 1 day to 6 months). The mean ages of the samples in 
these studies ranged from 27 to 68 years. Two studies recruited women only. Mean BMI in 
these studies was 26.1 kg/m2 (Table 1). Nine of the included studies assessed tomato 
products alone as the intervention agent [16-19, 27-29, 31, 32], seven studies used lycopene 
alone [20-26] and one study used both tomato products and lycopene [30]. The dose of 
tomato-products ranged from 70 to 400g/day, and lycopene dose ranged from 4 to 30mg/day. 
Two-thirds (n=12) of the reports included in the systematic review came from studies 
involving healthy participants (Table 1). The remaining studies reported the recruitment of 
participants with underlying cardiometabolic disorders (n=6), such as metabolic syndrome (1 
study), CVD (1 study), moderately overweight (1 studies), hypertensive (2 studies) and 
prehypertensive (1 study). 
Meta-analysis of studies supplementing tomato 
Six studies, including 401 participants, evaluated the impact of tomato supplementation on 
LDL-cholesterol. Overall, tomato supplementation significantly reduced LDL-cholesterol by 
0.22 mmol/L (95% CI -0.37 to -0.06; p=0.006). Heterogeneity levels assessed by the I2 test 
were low at 0% (Figure 2). 
Six studies, including 233 participants evaluated the impact of tomato supplementation on 
FMD. Three studies measured FMD acutely (≤24hours) and three studies evaluated FMD in 
the short term (≥ 1 week). Short-term tomato supplementation significantly increased FMD 
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by 2.53 percent (95% CI 0.56 to 4.50; p=0.01). Heterogeneity levels assessed by the I2 test 
were low at 0%; however acute studies did not show any improvements (Figure 3). 
There was only weak evidence that tomato interventions had an effect on other CV factors 
including SBP, DBP, Total- or HDL-cholesterol, triglycerides, Oxidised-LDL, or PWV 
(Supplementary material Figures S1-S7). 
Meta-analysis of studies supplementing lycopene 
Seven studies/arms, including 492 participants, evaluated the impact of lycopene 
supplementation on resting SBP. Overall lycopene supplementation significantly reduced 
SBP by 5.66 mmHg (95% CI -9.31 to -2.01; p=0.002). Heterogeneity levels assessed by the 
I2 test were significant at 65% (Figure 4). 
There was only weak evidence that lycopene interventions had an effect on other CV factors 
including DBP, Total- LDL- or HDL-cholesterol, triglycerides, Oxidised-LDL or PWV, 
(Supplementary material Figures S8-S14). 
Quality of studies 
We assessed the methodological quality and risk bias of the studies included in this review. 
The average retention rate for the RCTs included in this review was >90% for all studies and 
the reason for the dropouts were often not related to the interventions themselves. Therefore, 
the majority of the included studies satisfied the criteria of the quality assessment tool. 
Blinding of participants and researchers delivering the intervention was implemented in 
interventions testing lycopene supplements. In addition, the included studies provided an 
adequate description of methods and randomization procedures, thus no studies were 
excluded from analysis based on quality assessment.  
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Discussion 
Principal findings 
To our knowledge, this report is the first systematic assessment through meta-analysis of the 
effectiveness of tomato and lycopene supplementation on CV risk factors among adult 
subjects >18 years of age within RCTs. This systematic review and meta-analysis revealed 
that there is strong evidence indicating that tomato supplementation is associated with 
significant reductions in LDL-cholesterol and improvements in FMD, which in agreement 
with previous meta-analysis on lycopene being effective in reducing LDL-cholesterol [33]. 
However, tomato supplementation has no effect on other blood lipids or measures of 
endothelial function. In addition, lycopene supplementation was associated with significant 
reductions in SBP but not on any other cardiovascular marker. In a meta-analysis of Li and 
Xu (2013), indicated that lycopene supplementation can lowering SBP [34]. Together, these 
results indicate that consuming tomato products and or supplementing lycopene may have 
important health implications. This systematic review has also revealed that current studies 
have mostly focused on studying well-established cardiovascular biomarkers such as blood 
lipids and FMD as a measure of endothelial function, however the evidence on the effect of 
tomato products or lycopene supplementation on novel biomarkers of vascular risk is scarce 
at present and requires further investigation.  
 
Strengths and limitations  
The strengths of these findings include a rigorous methodology in the systematic review of 
the literature, the low levels of heterogeneity surrounding the results. It is of note that the 
intervention studies included in this review were consistently, and significantly, successful in 
modifying the outcomes above described. The overall quality of the studies was high. All 
studies were randomized, and double-blind in the case of lycopene supplementation. The 
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studies reported a high compliance with the interventions, which may be explained by the 
relatively short duration of the studies. 
This study is not without limitations. Due to the limited number of studies available, our 
analysis focused on examining the overall effects of interventions on the pre-specified 
outcomes preventing us of exploring the effects of common moderator variables such as age, 
gender, or other aspects of the interventions. This systematic review revealed that the 
evidence on the effect of tomato products or lycopene supplementation on novel biomarkers 
of CV risk is still scarce and needs further investigation. Overall, studies were characterized 
by a small sample size, short duration, and over-representation of young, healthy men. 
Heterogeneity was observed across lycopene supplementation, which could be due to the 
inconsistency of participants’ health status; healthy adults, hypertension, CVD patients and 
metabolic syndrome patients were collected. In addition, studies included in meta-analysis 
originated from different geographic regions, and the dietary patterns, genetic and sensitivity 
of lycopene might preform differently. We did not conduct subgroup analysis due to the 
limited studies. Therefore, we were not able to confirm the whether processing of tomatoes 
have strongly affect lycopene concentration and bioavailability. In addition, most of studies 
on the fresh tomato/ tomato juice did not provide the lycopene content.  We limited the 
choice of databases to three and although there might be a risk to have overlooked some 
studies, the databases included were considered the most relevant to the topic of study. 
 
Scientific analysis of findings 
This meta-analysis showed that tomato products supplementation was associated with 
significant reductions in LDL-cholesterol and improvements in short-term FMD, while 
lycopene supplementations reduced SBP. The beneficial effects of these interventions support 
the epidemiological evidence indicating an association between lower CVD risk and tomato 
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[5, 6] and suggest that these epidemiological findings may be explained by a potential 
combination of improvements in blood lipids, blood pressure, and endothelial function an 
early marker of cardiovascular risk [35].  
A number of potential mechanisms are probably responsible behind the findings of this 
systematic review. Lycopene, the major carotenoid in tomato, might be more important than 
other carotenoids in preventing atherosclerosis and cardiovascular diseases, however the 
findings from supplementing lycopene this systematic review did not support a role in 
reducing LDL-cholesterol. This may be related to the fact that tomatoes contain also other 
compounds (eg antioxidants such as vitamin C) possessing lipid-lowering properties 
associated with increased faecal excretion and reduced intestinal absorption of cholesterol, in 
addition to increasing cellular LDL receptor activity [28, 36].  
In addition, the results of the present meta-analysis are comparable to those achieved by other 
nutritional interventions such as dietary nitrates modifying SBP and FMD. In recent previous 
reports by our group, two systematic reviews of the literature showed that inorganic nitrate or 
beetroot juice consumption were associated with significant reductions in SBP (-4.4mmHg 
95% CI: -5.9, -2.8; P< 0.001) [3] , and improvements in FMD (SMD 0.52; 95 % CI 0.15, 
0.68; P = 0.002) [4].  
 
Implications for health and future research 
Our results showed a significant decline in vascular risk factors after short-term (1 day to 6 
months) tomato-products and lycopene (tomato-products doses from 70 to 400g/day, and 
lycopene dose ranged from 4 to 30mg/day) supplementation, which may potentially have 
important implications in primary and secondary prevention of atherosclerosis, 
cardiovascular diseases and cardiovascular mortality. The seventh report of the Joint National 
Committee on BP estimated that a systolic BP reduction of at least 5 mm Hg (similar to the 
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observed decline in SBP after Lycopene supplementation) could decrease the risk of 
mortality due to stroke by 13-14% [37, 38] and mortality from cardiovascular diseases by 9% 
[37]. In addition, reductions of 1 mmol in LDL-cholesterol have been associated with a 23% 
reduction in myocardial infarction or coronary death and 12% reduction in all-cause mortality 
[39]. In relation with our findings on FMD, several recent systematic reviews and meta-
analysis indicate that increases in FMD of 1% increase, independently of confounding 
factors, are associated with reductions ranging from 10-13% in the risk of cardiovascular 
events [40-42]. 
 
Conclusions 
The available evidence on the effects of tomato and lycopene supplementation on vascular 
risk factors supports the view that increasing the intake of these has positive effects on blood 
lipids, blood pressure and endothelial function. These results have potential public health 
implications and support the development of promising individualised nutritional strategies to 
tackle cardiovascular diseases.  
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Legends 
Figure1. PRISMA flow diagram of selection of studies on lycopene or tomato 
consumption and vascular risk factors 
 
 
Table 1. Characteristics of studies included in systematic review. 
M, Male; F, Female; RCT, randomised controlled trial; wk, weeks; BMI, Body mass 
index; TC, Total cholesterol; TG, Triglyceride; HDL, High density lipoprotein; LDL, 
Low density lipoprotein; OxLDL, Oxidised low-density lipoproteins; FMD, Flow-
mediated dilation; SBP, Systolic blood pressure, DBP, Diastolic blood pressure; PWV, 
Pulse wave velocity 
 
 
Figure 2. Meta-analysis of effect of interventions supplementing tomato on LDL 
cholesterol 
 
Figure 3. Meta-analysis of effect of interventions supplementing tomato on Flow 
mediated dilation (%) 
 
Figure 4. Meta-analysis of effect of interventions supplementing lycopene on systolic 
blood pressure (mmHg). 
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Reference 
(Country 
of origin)  
Health status Sample/Sex Age (SD) BMI Study design  Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Blum et al., 
2006 
(Israel) 
Healthy Tomato 
(M=16, 
F=34);  
Control 
(M=16, 
F=32) 
45.5±14.1 N/A Parallel,  
controlled 
4 wk Usual diet 
supplement 
with tomato  
300g tomato 
products per day 
Usual diet 
without tomato 
(no placebo) 
TC,  
TG, 
HDL, 
LDL 
Burton-
Freeman 
et al., 2012 
(USA) 
Healthy M=13; F=12 27±8 22 Crossover RCT 360 min Usual diet 
with tomato-
containing 
meal 
Around 85g of 
tomato paste 
Usual diet 
without tomato-
containing meal 
TG,  
OxLDL,  
FMD 
Collins et 
al., 2004 
(USA) 
Healthy M=5, F=5 M (49 (43-
68)); 
F (51 (35-63)) 
M=26.3; 
F=29.1 
Crossover, 
RCT 
3 wk Low lycopene 
diet 
supplemented 
tomato juice 
18.4mg lycopene 
per day 
Low lycopene 
diet 
TC,  
TG,  
HDL 
Cuevas-
Ramos et 
al., 2013 
(Mexico) 
Healthy Tomato 
(M=6, F=20);  
Control 
(M=5, F=19) 
42±15.5 27.1 Parallel, RCT, 
single-blind 
4 wk Usual diet 
supplemented 
with raw 
tomato 
300g of raw 
tomato per day 
Usual diet with 
300g of raw 
cucumber 
TC, 
TG, 
HDL,  
LDL 
Devaraj et 
al., 2008 
(USA) 
Healthy 6.5mg 
lycopene 
(M=4, F=17); 
15mg 
lycopene 
(M=4, F=13); 
30mg 
lycopene 
(M=7, F=14); 
Placebo 
(M=4, F=14) 
6.5mg 
lycopene 
(51.1±5.9); 
15mg 
lycopene 
(49.8±8.2); 
30mg 
lycopene 
(51.2±9.7); 
Placebo 
(49.9±15.8) 
6.5mg 
lycopene=29.6; 
15mg 
lycopene=25.4; 
30mg 
lycopene=26.4; 
Placebo=28.1 
Parallel, RCT, 
doubled-blind 
8 wk Lycopene 
restricted diet 
with 
supplemented 
lycopene  
capsules 
6.5, 15, or 30mg 
per day 
Placebo capsules 
(Lycopene 
restricted diet) 
TC, 
TG, 
HDL,  
LDL 
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Reference 
(Country 
of origin)  
Health status Sample/Sex Age (SD) BMI Study design  Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Engelhard 
et al., 2006 
(Israel) 
Hypertension, 
without 
concomitant 
diseases 
M=18, F=12 48 29.5 Non-
randomised 
single-blind 
placebo-
controlled 
trial 
8 wk Usual diet 
supplemented 
with lycopene 
capsule (Lyc-
O-Mato) 
250mg of tomato 
extract capsule 
containing 15mg 
lycopene per day 
Usual diet with 
identical-looking 
placebo capsule 
TC, 
TG, 
HDL,  
LDL, 
SBP, 
DBP 
Gajendrag
adkar et 
al., 2014 
(UK) 
Healthy and CVD 
patients 
Healthy 
(7mg M=23, 
F=1; control 
M=10, F=2); 
 
CVD patients 
(7mg M=15, 
F=9; control 
M=10, F=2)  
Healthy 
(7mg=61±13, 
control=68±5);  
 
CVD patients 
(7mg =67±6, 
control=68±5)  
Healthy 
(7mg=25.2; 
control=26.7); 
  
CVD patients 
(7mg 28.6; 
control=28.4)   
Parallel, RCT, 
double-blind 
8 wk Usual diet 
with lycopene 
capsule 
7mg lycopene 
daily per day 
Usual diet with 
identical-looking 
placebo capsule 
HDL, 
LDL,  
OxLDL, 
SBP, 
DBP, 
PWV 
Kim et al., 
2011 
(Korea) 
Healthy 6mg 
lycopene 
(n=41); 
15mg 
lycopene 
(n=37); 
Control 
(n=38) 
6mg lycopene 
(34.8±1.28); 
15mg 
lycopene 
(34.7±1.23); 
Control 
(33.5±1.13) 
6mg 
lycopene=25.3;  
 
15mg 
lycopene=23.9; 
 
Control=24.9 
Parallel, RCT, 
double-blind 
8 wk Usual diet 
supplemented 
with  lycopene 
capsules (Lyc-
O-Mato) 
6mg or 15mg 
lycopene per day 
Usual diet with 
placebo 
containing 
soybean oil 
capsules 
SBP 
Misra et 
al., 2006 
(India) 
Healthy 
postmenopausal 
women 
Lycopene 
supplement 
(F=20);  
Hormone 
replacement 
therapy 
(HRT) (F=21) 
46 Lycopene=25.8; 
 
HRT=25.3 
Parallel, RCT 6 months Lycopene 
capsule 
(LycoRed) 
2 lycopene 
capsules each 
containing 2mg of 
lycopene per day 
Hormone 
replacement 
therapy 
(estradiol 
valerate 2mg and 
norethisterone 
acetate 1mg) 
TC, 
TG, 
HDL, 
LDL 
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Reference 
(Country 
of origin)  
Health status Sample/Sex Age (SD) BMI Study design  Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Paran et 
al., 2009 
(Israel) 
Hypertension 
patient 
 M=26, F=24 61.4±8.9 N/A Crossover RCT 6 wk Usual diet 
supplemented 
with lycopene 
capsules (Lyc-
O-Mato) 
250mg of tomato 
extract capsule 
containing 15mg 
lycopene per day 
Usual diet with 
identical-looking 
placebo capsule 
SBP, 
DBP 
Ried et al., 
2009 
(Australia) 
Prehypertensive Lycopene 
(n=15);  
Control 
(n=10) 
Tomato 
extract 
(51.2±12.1);  
 
Control 
(57.9±13.4) 
N/A Parallel, RCT 8 wk Usual diet 
supplemented 
with lycopene 
capsules (Lyc-
O-Mato) 
Tomato extract 
capsule 
containing 15mg 
lycopene per day 
Usual diet 
supplemented 
with identical-
looking placebo 
capsule 
containing 
mainly soy oil 
SBP, 
DBP 
Samaras et 
al., 2014 
(Greece) 
Ultra-marathon 
runners 
Tomato 
Juice (n=15); 
Control 
(n=12) 
Tomato Juice 
(44.9±8.53); 
 
Control 
(46.6±15.3) 
Tomato 
Juice=24.1; 
 
Control=24.3 
Parallel, 
controlled 
8 wk Tomato juice Amount required 
to match subjects 
usual 
carbohydrate 
supplementation 
Continued any 
usual 
supplementation 
consumption 
TC, 
TG, 
HDL, 
LDL, 
FMD 
Silaste et 
al., 2007 
(Finland) 
Healthy  M=5; F=16 30 23.5 Sequential 3 
weeks low 
tomato, 
3 weeks high 
tomato 
6 wk Usual diet 
supplemented 
with tomato 
juice 
400ml  tomato 
juice containing 
27mg lycopene 
Usual diet 
without tomato 
products 
TC,  
LDL 
Stangl et 
al., 2011 
(Germany) 
Healthy 
postmenopausal 
women 
F=19 58.9±6.3 25 Crossover, 
RCT 
7 d Tomato free 
diet 
supplemented 
with buttered 
roll with 
tomato puree 
70g tomato puree 
containing 
46.2mg lycopene 
Tomato free diet 
supplemented 
with buttered roll 
without tomato 
puree 
FMD 
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Reference 
(Country 
of origin)  
Health status Sample/Sex Age (SD) BMI Study design  Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Thies et 
al., 2012 
(UK) 
Moderately 
overweight 
High tomato 
(M=35, 
F=46);  
Lycopene 
(M=28, 
F=40); 
Control 
(M=30, 
F=46) 
High tomato 
(51±0.7(SEM))
;  
Lycopene 
(51.1±0.9(SEM
);  
Control 
(51±0.7(SEM)) 
High 
tomato=26.4; 
 
Lycopene=26.7; 
 
Control=26.8 
Parallel, RCT,  
single-blind 
12 wk 1, High 
tomato based 
diet or  
 
2, low tomato 
diet 
supplemented 
with lycopene 
capsule 
1, High tomato 
diet were above 
the minimum 
target of 7mg per 
day 
 
2, Low tomato 
diet with 
lycopene capsules 
containing 10mg 
lycopene 
Low tomato diet 
(low in tomato-
based foods) 
TC,  
TG, 
HDL, 
LDL, 
OxLDL, 
SBP,  
DBP,  
PWV 
Tsitsimpik
ou et al., 
2014 
(Greece) 
Patients with 
metabolic 
syndrome 
Tomato 
(M=13, F=2);  
Control 
(M=11, F=1) 
Tomato 
(53.5±9.8); 
 
Control 
(56.6±10.2) 
N/A Parallel,  
controlled 
8 wk Usual diet 
supplemented 
with tomato 
juice 
Tomato juice with 
2.51mg lycopene 
per 100 ml 
Usual diet 
without tomato 
juice 
TC,  
TG, 
HDL,  
LDL 
Xaplanteris 
et al., 2012 
(Greece) 
Healthy  M=8, F=11 39±13 24.8 Crossover, 
RCT, single-
blinded 
2 wk usual diet 
supplemented 
with tomato 
paste  
70g of tomato 
paste containing 
33.3mg lycopene 
per day 
Usual diet 
without tomato 
paste 
FMD 
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Figure 1  
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Supplementary material 
 
Figure S1. Meta-analysis of effect of interventions supplementing tomato on total cholesterol 
(mmol/L). 
 
 
Figure S2. Meta-analysis of effect of interventions supplementing tomato on triglyceride 
(mmol/L). 
 
 
Figure S3. Meta-analysis of effect of interventions supplementing tomato on HDL 
cholesterol (mmol/L). 
 
 
Figure S4. Meta-analysis of effect of interventions supplementing tomato on Oxidised-LDL 
(mmol/L).  
 
 
Figure S5. Meta-analysis of effect of interventions supplementing tomato on systolic blood 
pressure (mmHg). 
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Figure S6. Meta-analysis of effect of interventions supplementing tomato on diastolic blood 
pressure (mmHg). 
 
 
Figure S7. Meta-analysis of effect of interventions supplementing tomato on pulse wave 
velocity (m/s). 
 
 
Figure S8. Meta-analysis of effect of interventions supplementing lycopene on total 
cholesterol (mmol/L). 
 
 
Figure S9. Meta-analysis of effect of interventions supplementing lycopene on triglyceride 
(mmol/L). 
 
 
Figure S10. Meta-analysis of effect of interventions supplementing lycopene on HDL 
cholesterol (mmol/L). 
 
 
Figure S11. Meta-analysis of effect of interventions supplementing lycopene on LDL 
cholesterol (mmol/L). 
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Figure S12. Meta-analysis of effect of interventions supplementing lycopene on Oxidised-
LDL (mmol/L).  
 
 
 
Figure S13. Meta-analysis of effect of interventions supplementing lycopene on diastolic 
blood pressure (mmHg). 
 
 
Figure S14. Meta-analysis of effect of interventions supplementing lycopene on pulse wave 
velocity (m/s). 
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Table S1. PRISMA checklist 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4-5 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4-5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
5 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5-6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
6 
31 
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6-7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
6-7 
 
 
 
 
